What’s Next for Adjuvant Therapy in Liver Cancer? Reflections on IMbrave050 and Beyond

In this video, Richard S. Finn, MD, of the Geffen School of Medicine at UCLA, and Adam Yopp, MD, of UT Southwestern Medical Center, discuss the challenges of defining high-risk patient populations in adjuvant trials for hepatocellular carcinoma, with a focus on the IMbrave050 study evaluating atezolizumab and bevacizumab. They explore why the trial results were not maintained over time and why upcoming studies, including EMERALD-2, CheckMate-9DX, and KEYNOTE-937, may also struggle to show a benefit.